{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-002350","form_type":"8-K","ticker":"CRMD","cik":"0001410098","company_name":"CorMedix Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.013208+00:00","generated_at":"2026-05-16T11:11:43.702913+00:00","sec_items":["2.02","5.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CorMedix preliminary Q4 revenue ~$127M, FY2025 pro forma ~$400M; CEO becomes Chairman, new CCO appointed","bullets":["Q4 2025 unaudited net revenue ~$127M; FY2025 pro forma net rev. ~$400M (incl. Melinta).","Q4 adjusted EBITDA guidance $77-81M; cash & short-term investments ~$148M.","FY2026 revenue guidance $300-320M; DefenCath rev. $150-170M; adj. EBITDA $100-125M.","CEO Todisco salary raised to $750k (from $665k); target bonus to 75% (from 65%); assumes Chairman role.","Appoints Mike Seckler as EVP & CCO; Phase 3 ReSPECT data expected Q2 2026; Analyst Day Feb 10."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-002350","json":"https://secwatch.observer/filing/0001213900-26-002350.json","markdown":"https://secwatch.observer/filing/0001213900-26-002350.md","text":"https://secwatch.observer/filing/0001213900-26-002350.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410098/000121390026002350/0001213900-26-002350-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410098/000121390026002350/ea0272149-8k_cormedix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:11:43.702913+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}